LexaGene Holdings files patent application to scale-up its LX Analyzer pathogen detection technology

LexaGene Holdings Inc (OTCQB:LXXGF) (CVE:LXG) said it has filed a provisional patent application with the US Patent and Trademark Office for expanding the testing capabilities of its pathogen-detecting LX Analyzer technology, which includes coronavirus (COVID-19) and other clinical lab testing.  The company plans to launch its flagship LX Analyzer in the third quarter with an eye on decentralized testing facilities in the clinical, veterinary, and food safety markets. The group said the technology is fully automated and ideally suited to look for coronavirus in emergency departments and physician practices to help facilitate their medical decisions in one hour or less, the company said. “Filing this new patent application is a significant step in expanding the capabilities of our technology, allowing us to meet the challenges of the high-throughput sample testing market,” CEO Jack Regan said in a statement. “Infectious disease testing is currently in high demand due to the COVID-19 pandemic, and with this filing, LexaGene is positioning itself to provide solutions both at point-of-need and at high-throughput reference laboratories," he added. READ: LexaGene hires seasoned executive as director of product marketing to help launch LX Analyzer LexaGene has seen demand for the technology from moderate to high-volume testing facilities, including centralized reference labs and large food production operations. LexaGene’s original design is scalable but doesn’t easily meet the scope of high-volume testers. To assuage those concerns, the company has filed a new provisional patent application covering a novel design of a fully integrated disposable cartridge that combines high-throughput sample processing with the company’s open-access multiplexing capabilities. “This new cartridge will allow a tester to process multiple samples simultaneously and will also allow them to test for a multitude of genetic targets using disposable components,” LexaGene's CEO said. “We expect the simple workflow, ease of use, and reduced waste offered by our new technology will facilitate easy adoption to ease the burden of testing laboratories. Innovation is the cornerstone of our technology, and this new filing will expand our intellectual property portfolio to protect new technologies that are under development.” Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com  Follow him on Twitter @andrew_kessel